HER2-Positive Breast Cancer
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates...
Leider schon ausverkauft
137.99 €
versandkostenfrei
68 DeutschlandCard Punkte
sammeln
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „HER2-Positive Breast Cancer “
Weitere Produktinformationen zu „HER2-Positive Breast Cancer “
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. Includes a timely section on innovative future therapies.
Bibliographische Angaben
- Autoren: Sara Hurvitz , Kelly McCann
- Verlag: ELSEVIER HEALTH SCIENCE
- EAN: 9780323581226
Inhaltsverzeichnis zu „HER2-Positive Breast Cancer “
Background/testing 1. The HER2 alteration in breast cancer2. HER2 testing in the era of changing guidelines
Advanced Disease3. Optimal first-line treatment of HER2+ advanced disease4. Second line therapy and beyond5. HER2+ CNS metastasesTherapeutics6. Neoadjuvant therapy7. Adjuvant therapy8. Outcomes based on HR status in early stage disease9. De-escalation of therapy for small tumor
Toxicity considerations10. Cardiac toxicity of HER2-targeted regimens11. Non-cardiac toxicity of HER2-targeted therapy
Therapies on the horizon12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)13. Harnessing the immune system in HER2+ disease14. Biosimilars
Kommentar zu "HER2-Positive Breast Cancer"
0 Gebrauchte Artikel zu „HER2-Positive Breast Cancer“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "HER2-Positive Breast Cancer".
Kommentar verfassen